On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its ...

Q3 2025 Management View Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility ...

Bio-Rad Laboratories, Inc. today announced the launch of new PrimePCR Droplet Digital PCR (ddPCR™) Assays. This release expands Bio-Rad’s offering of predesigned validated copy number assays to a ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication ...

Bio-Rad Laboratories, Inc. BIO announced that the performance of its QX200 Droplet Digital polymerase chain reaction (PCR) (ddPCR) System for the clinical detection of SARS-CoV-2 was proved to be more ...